Business
Catalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business Update
Catalyst Enters 2025 With Strong Momentum; Reiterates Confidence in Full-Year Outlook Delivers Record Q1 2025 Total Revenues of $141.4 Million, a 43.6% YoY
About this update from Catalyst Pharmaceuticals, Inc.
[{"type":"text","content":"Catalyst Enters 2025 With Strong Momentum; Reiterates Confidence in Full-Year Outlook Delivers Record Q1 2025 Total Revenues of $141.4 Million, a 43.6% YoY Increase FIRDAPSE® and AGAMREE® Drive Sustained Organic Growth, Underscoring Execution Strength Reaffirms Full-Year 2025 Total Revenue Guidance Provided Earlier This Year of Between $545 Million and $565 MillionStrengthens Balance Sheet with Cash and Cash Equivalents of $580.7 Million and No Debt as of March 31, 2025 Conference Call and Webcast to be Held on May 8, 2025, at 8:30 AM ET CORAL GABLES, Fla., May 07, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (\"Catalyst\" or \"Company\") (Nasdaq: CPRX), today reported financial results for the first quarter of 2025 and provided a business update. \"Catalyst's exceptional first quarter performance underscores the continued strength of our commercial strategy and the growing demand for our differentiated therapies,\" said Richard J. Daly, President and CEO of Catalyst. \"Our 43.6% year-over-year total revenue growth for the first quarter of 2025 is a testament to our focused execution and the increasing recognition of the value that our therapies deliver. Looking ahead, we see meaningful opportunities to further establish AGAMREE as a cornerstone therapy in the Duchenne muscular dystrophy (DMD) market and expand FIRDAPSE's clinical utility in Lambert-Eaton myasthenic syndrome (LEMS), addressing a significant unmet need for patients in both markets. We continue to evaluate strategically aligned opportunities to strengthen our portfolio and expand our reach to serve more patients. Building on our momentum, we are confident in our ability to execute our 2025 strategic priorities and drive long-term growth.\" Financial Highlights For the Three Months Ended March 31, 2025 2024% Change (In thousands, except per share data) Product Revenue, net$141,400$98,44143.6%FIRDAPSE Product Revenue, net$83,731$66,84225.3%FYCOMPA Product Revenue, net$35,627$30,42517.1%AGAMREE Product Revenue, net*$22,042$1,1741,777.5%GAAP Net Income$56,737$23,275143.8%Non-GAAP Net Income **$86,596$46,76785.2% GAAP Net Income Per Share – Basic$0.47$0.20135.0%Non-GAAP Net Income Per Share – Basic**$0.71$0.4077.5% GAAP Net Income Per Share – Diluted$0.45$0.19136.8%Non-GAAP Net Income Per Share – Diluted**$0.68$0.3878.9% As of March 31, 2025 and December 31,...